阿司匹林用于循证子痫前期预防试验:阿司匹林对新生儿重症监护病房住院时间的影响
该研究为阿司匹林用于循证子痫前期预防试验的二次分析,纳入1620例参与者、1571例活产儿。高危孕妇使用阿司匹林150 mg/d较安慰剂显著缩短新生儿重症监护病房平均住院时间(11.1 vs 31.4天),总住院天数安慰剂组1696天 vs 阿司匹林组531天。
要点
- 高危孕妇阿司匹林150 mg/d较安慰剂缩短新生儿重症监护病房平均住院时间20.3天。
- 阿司匹林组<32周分娩活产儿9例(1.2%)vs 安慰剂组23例(2.9%),比值比0.42。
- 全人群平均住院时间安慰剂组2.06天 vs 阿司匹林组0.66天,降低1.4天。
核心结论
- 在高危子痫前期妊娠中,使用阿司匹林使新生儿重症监护病房住院时间缩短约70%,主要归因于<32周分娩率降低,主要因预防早发型子痫前期。
研究设计与样本
- 阿司匹林用于循证子痫前期预防试验的二次分析,评估阿司匹林对新生儿重症监护病房住院时间影响的差异。
- 试验共1620例参与者,1571例活产儿;采用自举法比较阿司匹林组与安慰剂组平均住院时间,采用逻辑回归评估治疗对新生儿重症监护病房住院的影响。
主要发现
- 新生儿重症监护病房总住院时间安慰剂组1696天 vs 阿司匹林组531天。
- 入住新生儿重症监护病房的婴儿平均住院时间阿司匹林组11.1天 vs 安慰剂组31.4天,缩短20.3天(95%CI 7.0-38.6;P=0.008)。
- <32周分娩婴儿的新生儿重症监护占两个治疗组总2227天中的1856天(83.3%),阿司匹林组777例活产中9例(1.2%) vs 安慰剂组794例中23例(2.9%)(OR 0.42;95%CI 0.19-0.93;P=0.033)。
- 全人群(未入住新生儿重症监护者住院时间计为0)平均住院时间安慰剂组2.06天 vs 阿司匹林组0.66天,降低1.4天(95%CI 0.45-2.81;P=0.014),相当于住院时间降低68%(95%CI 20-86%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preeclampsia is a major pregnancy complication with adverse short- and long-term implications for both the mother and baby. Screening for preeclampsia at 11-13 weeks' gestation by a combination of maternal demographic characteristics and medical history with measurements of biomarkers can identify about 75% of women who develop preterm preeclampsia with delivery at <37 weeks' gestation and 90% of those with early preeclampsia at <32 weeks, at a screen-positive rate of 10%. A recent trial (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention) has reported that in women identified by first-trimester screening as being at high risk for preeclampsia, use of aspirin (150 mg/d from the first to the third trimester), compared to placebo, reduced the incidence of preterm preeclampsia, which was the primary outcome, by 62% (95% confidence interval, 26-80%) and the incidence of early preeclampsia by 89% (95% confidence interval, 53-97%). The surprising finding of the trial was that despite the reduction in preeclampsia the incidence of admission to the neonatal intensive care unit, which was one of the secondary outcomes, was not significantly affected (odds ratio, 0.93; 95% confidence interval, 0.62-1.40). OBJECTIVE: We sought to examine the effect of prophylactic use of aspirin during pregnancy in women at high risk of preeclampsia on length of stay in the neonatal intensive care unit. STUDY DESIGN: This was a secondary analysis of data from the Aspirin for Evidence-Based Preeclampsia Prevention trial to assess evidence of differences in the effect of aspirin on length of stay in neonatal intensive care. Bootstrapping was used for the comparison of mean length of stay between the aspirin and placebo groups. Logistic regression was used to assess treatment effects on stay in the neonatal intensive care unit. RESULTS: In the trial there were 1620 participants and 1571 neonates were liveborn. The total length of stay in neonatal intensive care was substantially longer in the placebo than aspirin group (1696 vs 531 days). This is a reflection of significantly shorter mean lengths of stay in babies admitted to the neonatal intensive care unit from the aspirin than the placebo group (11.1 vs 31.4 days), a reduction of 20.3 days (95% confidence interval, 7.0-38.6; P = .008). Neonatal intensive care of babies born at <32 weeks' gestation contributed 1856 (83.3%) of the total of 2227 days in intensive care across both treatment arms. These occurred in 9 (1.2%) of the 777 livebirths in the aspirin group and in 23 (2.9%) of 794 in the placebo group (odds ratio, 0.42; 95% confidence interval, 0.19-0.93; P = .033). Overall, in the whole population, including 0 lengths of stay for those not admitted to the neonatal intensive care unit, the mean length of stay was longer in the placebo than aspirin group (2.06 vs 0.66 days; reduction of 1.4 days; 95% confidence interval, 0.45-2.81; P = .014). This corresponds to a reduction in length of stay of 68% (95% confidence interval, 20-86%). CONCLUSION: In pregnancies at high risk of preeclampsia administration of aspirin reduces the length of stay in the neonatal intensive care unit by about 70%. This reduction could essentially be attributed to a decrease in the rate of births at <32 weeks' gestation, mainly because of prevention of early preeclampsia. The findings have implications for both short- and long-term health care costs as well as infant survival and handicap.
引用
- Wright D, Rolnik DL, Syngelaki A, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol. 2018. PMID: 29505771. doi:10.1016/j.ajog.2018.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。